{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-037689","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.306373+00:00","generated_at":"2026-05-29T02:28:35.592263+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eton Pharma announces PKU GOLIKE trial shows statistically significant metabolic control improvement","bullets":["PKU GOLIKE showed statistically significant reduction in blood Phe (P=0.0002) and increase in Tyr (P=0.0113) vs standard substitutes during overnight fasting.","Average 17.8% reduction in Phe (P=0.0484) and 33.8% increase in Tyr (P=0.0008) from baseline with PKU GOLIKE; standard substitutes led to 27.6% Phe increase.","Study was randomized crossover in pediatric classical PKU patients at Birmingham Children's Hospital; results to be presented at ACMG 2025.","Eton expects data to promote adoption of PKU GOLIKE; product is marketed via existing metabolic sales force."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-037689","json":"https://secwatch.observer/filing/0001437749-24-037689.json","markdown":"https://secwatch.observer/filing/0001437749-24-037689.md","text":"https://secwatch.observer/filing/0001437749-24-037689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924037689/0001437749-24-037689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924037689/eton20241216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:28:35.592263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}